Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 264

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients

Wolffenbuttel, B. H. R., Gomis, R., Squatrito, S., Jones, N. P., Patwardhan, R. N.·2000·Diabetic Medicine

Abstract

Summary: Aims This study was designed to test the efficacy and safety of low‐dose rosiglitazone, a potent, insulin‐sensitizing thiazolidinedione, in combination with sulphonylurea in Type 2 diabetic patients. Methods For the intention‐to‐treat analysis, 574 patients (59% male, mean age 61 years) were available, randomized to receive 26 weeks of twice‐daily placebo (n = 192), rosiglitazone 1 mg (n = 199) or rosiglitazone 2 mg (n = 183) in addition to existing sulphonylurea treatment with gliclazide (47.6% of patients), glibenclamide (41.8%) or glipizide (9.4%) (two patients were taking carbutamide or glimepiride). Change in haemoglobin A 1c (HbA 1c), fasting plasma glucose (FPG), fructosamine, insulin, C‐peptide, albumin, and lipids were measured, and safety was evaluated. Results Mean baseline HbA 1c was 9.2% and FPG was 11.4 mmol/l. Rosiglitazone at doses of 1 and 2 mg b.d. plus sulphonylurea produced significant decreases, compared with sulphonylurea plus placebo, in HbA 1c (−0.59% and −1.03%, respectively; both P < 0.0001) and FPG (1.35 mmol/l and 2.44 mmol/l, respectively; both P < 0.0001). Both HDL‐cholesterol and LDL‐cholesterol increased and potentially beneficial decreases in non‐esterified fatty acids and gamma glutamyl transpeptidase levels were seen in both rosiglitazone groups. The overall incidence of adverse experiences was similar in all three treatment groups, with no significant cardiac events, hypoglycaemia or hepatotoxicity. Conclusions Overall, the combination of rosiglitazone and a sulphonylurea was safe, well tolerated and effective in patients with Type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1464-5491.2000.00224.x

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 264

Metadata

Authors
Wolffenbuttel, B. H. R., Gomis, R., Squatrito, S., Jones, N. P., & Patwardhan, R. N.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2000-01
Volume
17
Issue
1
Pages
40-47
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2169421904
Cited by
264
References
26
FWCI
24.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. https://app.cochat.ai/papers/10.1046/j.1464-5491.2000.00224.x
The paper
Wolffenbuttel, B. H. R., Gomis, R., Squatrito, S., Jones, N. P., & Patwardhan, R. N. (2000). Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabetic Medicine. https://doi.org/10.1046/j.1464-5491.2000.00224.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.